ArticlePloS one2013
IL-23 induces atopic dermatitis-like inflammation instead of psoriasis-like inflammation in CCR2-deficient mice.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- The evaluation of the plasma levels of interleukin 17A, thymic stromal lymphopoietin, interferon gamma, tumor necrosis factor-alpha and interleukins IL-2, IL-6, IL-23, and IL-31 in atopic dermatitis patients with dupilumab treatment.Frontiers in immunology · 2026Article
- Assessment of gene signatures following the inhibition of IL-23: a study to evaluate the mechanistic effects behind the clinical efficacy of guselkumab in patients with psoriatic arthritis.Frontiers in immunology · 2025Article
- Sprayable inflammasome-inhibiting lipid nanorods in a polymeric scaffold for psoriasis therapy.Nature communications · 2024Article
- Interplay of cytokines in the pathophysiology of atopic dermatitis: insights from Murin models and human.Frontiers in medicine · 2024Review
- Preclinical Models of Atopic Dermatitis Suitable for Mechanistic and Therapeutic Investigations.Journal of inflammation research · 2024Review
- Inflammatory Cues Direct Skin-Resident Type 1 Innate Lymphoid Cells to Adopt a Psoriasis-Promoting Identity.JID innovations : skin science from molecules to population health · 2023Article
- Proteomic and Metabolomic Changes in Psoriasis Preclinical and Clinical Aspects.International journal of molecular sciences · 2023Review
- Antimony Compounds Associate with Atopic Dermatitis and Influence Models of Itch and Dysbiosis.Environmental science & technology letters · 2023Article
- Genomic control of inflammation in experimental atopic dermatitis.Scientific reports · 2022Article
- Translational Relevance of Mouse Models of Atopic Dermatitis.Journal of clinical medicine · 2021Review
- Biological therapies for atopic dermatitis: An update.Experimental and therapeutic medicine · 2019Review
- The Unique Molecular Signatures of Contact Dermatitis and Implications for Treatment.Clinical reviews in allergy & immunology · 2019Review
- RIG-I antiviral signaling drives interleukin-23 production and psoriasis-like skin disease.EMBO molecular medicine · 2017Article
- Monocyte-derived inflammatory Langerhans cells and dermal dendritic cells mediate psoriasis-like inflammation.Nature communications · 2016Article
- Human papillomavirus e7 oncoprotein transgenic skin develops an enhanced inflammatory response to 2,4-dinitrochlorobenzene by an arginase-1-dependent mechanism.The Journal of investigative dermatology · 2014Article
- The role of AhR in autoimmune regulation and its potential as a therapeutic target against CD4 T cell mediated inflammatory disorder.International journal of molecular sciences · 2014Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Psoriasis is an immune-mediated chronic inflammatory skin disease, characterized by epidermal hyperplasia and infiltration of leukocytes into the dermis and epidermis. IL-23 is expressed in psoriatic skin, and IL-23 injected into the skin of mice produces IL-22-dependent dermal inflammation and acanthosis. The chemokine receptor CCR2 has been implicated in the pathogenesis of several inflammatory diseases, including psoriasis. CCR2-positive cells and the CCR2 ligand, CCL2 are abundant in psoriatic lesions. To examine the requirement of CCR2 in the development of IL-23-induced cutaneous inflammation, we injected the ears of wild-type (WT) and CCR2-deficient (CCR2(-/-)) mice with IL-23. CCR2(-/-) mice had increased ear swelling and epidermal thickening, which was correlated with increased cutaneous IL-4 levels and increased numbers of eosinophils within the skin. In addition, TSLP, a cytokine known to promote and amplify T helper cell type 2 (Th2) immune responses, was also increased within the inflamed skin of CCR2(-/-) mice. Our data suggest that increased levels of TSLP in CCR2(-/-) mice may contribute to the propensity of these mice to develop increased Th2-type immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.